Separately, HC Wainwright set a $3.00 price objective on shares of Soligenix and gave the company a hold rating in a research report on Friday, March 16th.
Shares of Soligenix stock opened at $1.92 on Thursday. The company has a market cap of $16.78, a price-to-earnings ratio of -1.85 and a beta of 0.46. Soligenix has a 52-week low of $1.74 and a 52-week high of $5.08.
Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates through two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, including pediatric Crohn's disease and acute radiation enteritis.
Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with MarketBeat.com's FREE daily email newsletter.